Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 2/2004

01.02.2004 | Leading Article

Antiepileptic-Induced Resistance to Neuromuscular Blockers

Mechanisms and Clinical Significance

verfasst von: Associate Professor Sulpicio G. Soriano, J. A. Jeevendra Martyn

Erschienen in: Clinical Pharmacokinetics | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Abstract Prolonged administration of antiepileptic drugs is associated with several drug interactions. In the field of anaesthesia and critical care, patients exhibit both sensitivity and resistance to non-depolarising neuromuscular blockers (NDNMBs) after acute and long-term administration of antiepileptic drugs, respectively. Although antiepileptic therapy alone has only mild neuromuscular effects, acutely administered antiepileptic drugs can potentiate the neuromuscular effects of NDNMBs as a result of direct pre- and post-junctional effects. Resistance to NDNMBs during long-term antiepileptic therapy is due to multiple factors operating alone or in combination, including induction of hepatic drug metabolism, increased protein binding of the NDNMBs and/or upregulation of acetylcholine receptors.
Literatur
1.
Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 1987; 66: 691–3PubMedCrossRef
2.
Ornstein E, Matteo RS, Young WL, et al. Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. Anesthesiology 1985; 63: 294–8PubMedCrossRef
3.
Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced resistance to pancuronium: use of atracurium infusion in management of a neurosurgical patient. Anaesthesia 1988; 43(9): 757–9PubMedCrossRef
4.
Alloul K, Whalley DG, Shutway F, et al. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology 1996; 84: 330–9PubMedCrossRef
5.
Soriano SG, Sullivan LJ, Venkatakrishnan K, et al. Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. Br J Anaesth 2001; 86(2): 223–9PubMedCrossRef
6.
Spacek A, Neiger FX, Krenn CG, et al. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 1999; 90: 109–12PubMedCrossRef
7.
Soriano SG, Kaus SJ, Sullivan LJ, et al. Onset and duration of action of rocuronium in children receiving chronic anticonvulsant therapy. Paediatr Anaesth 2000; 10: 133–6PubMedCrossRef
8.
Jellish WS, Modica PA, Tempelhoff R. Accelerated recovery from pipecuronium in patients treatment with chronic anticonvulsant therapy. J Clin Anesth 1993; 5: 105–8PubMedCrossRef
9.
Hans P, Ledoux D, Bonhomme V, et al. Effect of plasma anticonvulsant level on pipecuronium-induced neuromuscular blockade. J Neurosurg Anesthesiol 1995; 4: 254–8CrossRef
10.
Tempelhoff R, Modica PA, Jellish WS. Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990; 71: 665–9PubMedCrossRef
11.
Ornstein E, Matteo RS, Schwartz AE, et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987; 67: 191–6PubMedCrossRef
12.
Spacek A, Neiger FX, Spiss CK, et al. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine. Acta Anaesthesiol Scand 1997; 41: 1308–11PubMedCrossRef
13.
Ornstein E, Matteo RS, Weinstein JA, et al. Accelerated recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic anticonvulsant therapy. J Clin Anesth 1991; 3(2): 108–11PubMedCrossRef
14.
Spacek A, Neiger FX, Spiss CK, et al. Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular blockade. Br J Anaesth 1996; 77: 500–2PubMedCrossRef
15.
Jellish WS, Thalji Z, Brundidge PK, et al. Recovery from mivacurium-induced neuromuscular blockade is not affected by anticonvulsant therapy. J Neurosurg Anesthesiol 1996; 8: 4–8PubMedCrossRef
16.
Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002; 96(1): 202–31PubMedCrossRef
17.
Martyn JAJ. Basic and clinical pharmacology of the acetylcholine receptor: implication for the use of neuromuscular relaxants. Keio J Med 1995; 44: 1–8PubMedCrossRef
18.
Moorthy SS, Krishna G, Dierdorf SF. Resistance to vecuronium in patients with cerebral palsy. Anesth Analg 1991; 73(3): 275–7PubMedCrossRef
19.
Theroux MC, Akins RE, Barone C, et al. Neuromuscular junctions in cerebral palsy: presence of extrajunctional acetylcholine receptors. Anesthesiology 2002; 96(2): 330–5PubMedCrossRef
20.
Shayevitz JR, Matteo RS. Decreased sensitivity to metocurine in patients with upper motoneuron disease. Anesth Analg 1985; 64(8): 767–72PubMedCrossRef
21.
Ibebunjo C, Martyn JA. Fiber atrophy, but not changes in acetylcholine receptor expression, contributes to the muscle dysfunction after immobilization. Crit Care Med 1999; 27(2): 275–85PubMedCrossRef
22.
Ibebunjo C, Nosek MT, Itani MS, et al. Mechanisms for the paradoxical resistance to d-tubocurarine during immobilization-induced muscle atrophy. J Pharmacol Exp Ther 1997; 283: 443–51PubMed
23.
Waud BE, Waud DR. The relation between tetanic fade and receptor occlusion in the presence of competitive neuromuscular block. Anesthesiology 1971; 35(5): 456–64PubMedCrossRef
24.
Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32(5): 554–63PubMedCrossRef
25.
Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24(1): 91–103PubMedCrossRef
26.
Devlin JC, Head-Rapson AG, Parker CJ, et al. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993; 71(2): 227–31PubMedCrossRef
27.
Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986; 65(1): 6–12PubMedCrossRef
28.
Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83(5): 1065–71PubMed
29.
Martyn JA, Goudsouzian NG, Chang Y, et al. Neuromuscular effects of mivacurium. Anesthesiology 2000; 92(1): 31–7PubMedCrossRef
30.
Atherton DP, Hunter JM. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet 1999; 36(3): 169–89PubMedCrossRef
31.
Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9(3): 156–84PubMedCrossRef
32.
Honkakoski P, Auriola S, Lang MA. Distinct induction profiles of three phenobarbital-responsive mouse liver cytochrome P450 isozymes. Biochem Pharmacol 1992; 43(10): 2121–8PubMedCrossRef
33.
Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347(Pt 2): 321–37PubMedCrossRef
34.
Pirttiaho HI, Sotaniemi EA, Pelkonen RO, et al. Hepatic blood flow and drug metabolism in patients on enzyme-inducting anticonvulsants. Eur J Clin Pharmacol 1982; 22: 441–5PubMedCrossRef
35.
Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 18(3): 401–10PubMedCrossRef
36.
Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33(1): 139–44PubMedCrossRef
37.
Patsalos PN, Duncan JS, Shorvon SD. Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy. Br J Clin Pharmacol 1988; 26(3): 253–9PubMedCrossRef
38.
Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia 1991; 32(1): 101–15PubMedCrossRef
39.
Wen X, Wang JS, Kivisto KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52(5): 547–53PubMedCrossRef
40.
Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: S8–13PubMedCrossRef
41.
Wood M. Plasma binding and limitation of drug access to site of action. Anesthesiology 1991; 75: 721–3PubMedCrossRef
42.
Abramson FP. Parallel induction of plasma alpha 1-acid glycoprotein concentration and antipyrine clearance by drugs. Prog Clin Biol Res 1989; 300: 427–35PubMed
43.
Contin M, Riva R, Albani F, et al. Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy. Eur J Clin Pharmacol 1985; 29(2): 211–4PubMedCrossRef
44.
Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1–47PubMed
45.
Fink H, Blobner M, Martyn JAJ. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors. Anesthesiology 2003; 98: 82–8PubMedCrossRef
46.
Martyn JAJ, Wang C, Itani MS. α1-acid glycoprotein but not albumin can reverse the neuromuscular effects of d-tubocurarine in mice [abstract]. Anesth Analg 1993; 76: S245
47.
Gray HS, Slater RM, Pollard BJ. The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade. Anaesthesia 1989; 44: 379–81PubMedCrossRef
48.
Norris FH, Colella J, McFarlin D. Effect of diphenylhydantoin on neuromuscular synapse. Neurology 1968; 14: 869–76CrossRef
49.
Pincus JH, Yaari Y, Argov Z. Phenytoin: electrophysiological effects at the neuromuscular junction. Adv Neurol 1980; 27: 363–76PubMed
50.
Nguyen A, Ramzan I. Acute in vitro neuromuscular effects of carbamazepine and carbamazepine-10-11-epoxide. Anesth Analg 1997; 84: 886–90PubMed
51.
Nguyen A, Ramzan I. In vitro neuromuscular effects of valproic acid. Br J Anaesth 1997; 78(2): 197–200PubMedCrossRef
52.
Hogue Jr CW, Ward JM, Itani MS, et al. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol 1992; 72(4): 1326–31PubMed
53.
Kim CS, Arnold FJ, Itani MS, et al. Decreased sensitivity to metocurine during long term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. Anesthesiology 1992; 77: 500–6PubMedCrossRef
54.
Brotherton WP, Matteo RS. Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. Anesthesiology 1981; 55(3): 273–6PubMedCrossRef
55.
Platt PR, Thackray NM. Phenytoin-induced resistance to vecuronium. Anaesth Intensive Care 1993; 21: 185–91PubMed
56.
Whalley DG, Ebrahim ZY. Influence of carbamazepine on the dose-response relationship of vecuronium. Br J Anaesth 1994; 72: 125–6PubMedCrossRef
57.
Tempelhoff R, Modica PA, Spitznagel EL. Anticonvulsants therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth 1990; 37: 327–32PubMedCrossRef
58.
Martyn JA, Greenblatt DJ. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 1984; 35: 535–9PubMedCrossRef
59.
Hans P, Brichant JF, Pieron F, et al. Elevated plasma alpha1-acid glycoprotein levels: lack of connection to resistance to vecuronium blockade induced by anticonvulsant therapy. J Neurosurg Anesthesiol 1997; 9: 3–7PubMedCrossRef
60.
Spacek A, Nickl S, Neiger FX, et al. Augmentation of the rocuronium-induced neuromuscular block by the acutely administered phenytoin. Anesthesiology 1999; 90(6): 1551–5PubMedCrossRef
61.
Martyn JA, White DA, Gronert GA, et al. Up-and-down regulation of skeletal muscle acetylcholine receptors: effects on neuromuscular blockers. Anesthesiology 1992; 76(5): 822–43PubMedCrossRef
62.
Melton AT, Antognini JF, Gronert GA. Prolonged duration of succinylcholine in patients receiving anticonvulsants: evidence for mild upregulation of acetylcholine receptors?. Can J Anaesth 1993; 40: 939–42PubMedCrossRef
63.
Theroux MC, Brandom BW, Zagnoev M, et al. Dose response of succinylcholine at the adductor pollicis of children with cerebral palsy during propofol and nitrous oxide anesthesia. Anesth Analg 1994; 79(4): 761–5PubMedCrossRef
Metadaten
Titel
Antiepileptic-Induced Resistance to Neuromuscular Blockers
Mechanisms and Clinical Significance
verfasst von
Associate Professor Sulpicio G. Soriano
J. A. Jeevendra Martyn
Publikationsdatum
01.02.2004
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 2/2004
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200443020-00001

Weitere Artikel der Ausgabe 2/2004

Clinical Pharmacokinetics 2/2004 Zur Ausgabe

Review Article

Clinical Pharmacokinetics of Everolimus

Review Article

Clinical Pharmacokinetics of Nateglinide

Original Research Article

Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy

Original Research Article

Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers